$LIMN News

Liminatus Pharma Enters Warrant Exercise Agreement With Existing Investors To Purchase 10,344,000 Shares At $0.18 Per Share

Liminatus Pharma Announces Nasdaq Delisting Notification

Liminatus Pharma Entered Definitive Agreement To Acquire InnocsAI On May 17 In $320M All-Stock Transaction

Liminatus Pharma Is Trending Overnight — Here's Why LIMN Stock Surged Over 79% In After-Hours Session

Liminatus Pharma Enters Merger Agreement With InnocsAI On May 17, 2026; InnocsAI Members To Receive 1.6B Shares At $0.20 Per Share And 20% Contingent Value Rights

Liminatus Pharma Announces Planned Phase 1 Clinical Trial of IBA101, a Next-Generation CD47 Blocking Antibody

Liminatus Intends To Start Phase 1 Clinical Study Of CD47-Blocking Monoclonal Antibody

Liminatus Pharma, Inc. Announces Pricing of $4.0 Million Public Offering

Gold Down 3%; Medtronic Earnings Top Views

12 Health Care Stocks Moving In Tuesday's Intraday Session

Liminatus Pharma shares are trading lower after the company announced pricing of $4.0 million public offering.

Liminatus Pharma shares are trading lower after the company announced pricing of $4.0 million public offering.

US Stocks Mixed; NY Manufacturing Activity Falls In February

Liminatus Announces $4M Public Offering; 13,813,000 Common Stock Shares On Offer At $0.29/Share

On Monday, there are stocks with unusual volume. Let's take a look.

Liminatus Pharma Agrees To Issue 4M Common Shares To Clear Street As Part Of Settlement

Curious about the stocks that are showing activity after the closing bell on Friday?

12 Health Care Stocks Moving In Friday's After-Market Session

Here are the top movers in Thursday's session.

Thursday's session: top gainers and losers